PubMed Health⌕ Search

Biomedical subjects

A Circolo

Publications and source records attributed to A Circolo.

32 records · Page 2Linked to original sources
PubMed1985

Binding and activation of hemolytic complement by IgG antibodies: cooperativity between antibodies of different hapten specificity.

The ability of IgG antibodies with different hapten specificities to fix C1 and activate C as a function of hapten density on a red cell surface was investigated. Rabbit anti-methotrexate and anti-folinic acid IgG antibodies in a mixture were highly efficient in fixing C1 and activating C when cells carried simultaneously high levels of both haptens. We wished to find out whether in a C-activating IgG complex both IgG molecules had to be in a form that could activate C1. By reducing hapten density of one of the haptens on a double labeled cell, complexes were generated where only one in a pair of IgG molecules was in the activating form; such a pair had the same activating efficiency as a pair in which both IgG molecules were in the activating form. It was concluded that cooperative activation of C in C1-binding IgG complexes required only one IgG in the complex to be in the activating form.

Animals↗
PubMed1984

Lack of binding of C3 to IgG antibodies during the activation of the classical complement pathway on the red cell.

We have studied the interaction between C3 and natural human and rabbit anti-MTX IgM and hyperimmune IgG antibody bound to red cells to which MTX was covalently coupled. IgM Ab molecules bound to the cell surface were measured by their interaction with rabbit anti-human mu-chain IgG Ab: the bound anti-mu-chain or anti-MTX IgG was quantitated with 125I-labelled PA. C3 uptake by EMTX AC142 complexes from purified preparation of C3 was detected by the interaction of bound C3 with rabbit anti-C3 IgG Ab; the bound IgG was then measured with radiolabelled PA. In some experiments the uptake of C3 by the EMTX AC142 complexes was measured by using 125I-labelled C3. To find out if C3 was bound to Ab molecules, anti-MTX Abs were eluted from the cells by excess fluid-phase MTX. After dialysis the eluted anti-MTX IgM or IgG Ab was than reattached to fresh EMTX. All cells were then analyzed for Ab and C3 content by a radioimmunoassay. It was found that when anti-MTX IgM or IgG was eluted from EMTX AC423 complexes no C3 was removed from the cells and that eluted IgM or IgG did not carry with them either C3 antigen or 125I-labelled C3. It was concluded that, during the activation of the classical C-pathway at the red cell surface, no C3 was bound to IgM (rabbit or human) or IgG (rabbit) antibody molecules.

Animals↗
PubMed1984

Lysis of sheep red cells in neat autologous serum as a source of antibody and complement.

Lysis of autologous sheep red cells (labeled with methotrexate as the target hapten) by neat autologous serum was studied. The results indicated that the efficiency of lysis under physiological concentrations of cells and serum was about the same as lysis of the same target cells sensitized with autologous antibody and guinea pig serum as the source of complement. The data also indicate that the one-hit mechanism of immune lysis operates under near physiological conditions.

Animals↗
PubMed1983

Binding and activation of C1 by cell bound IgG: activation depends on cell surface hapten density.

We have investigated the binding and activation of C1 by IgG-anti methotrexate antibody at cell surfaces. Under conditions where variation in cell surface hapten density had no effect on binding of IgG, the number of C1 (or its active form, C1) bound by the IgG was independent of hapten density. The ability of the C1 binding IgG complex to activate C1, however, was decreased with decreasing density of the hapten. The decreased ability to activate bound C1 was paralleled by decreased ability to activate the hemolytic sequence in whole complement. The results were interpreted to mean that binding of C1 was the result of aggregation (doublet formation) by IgG while activation of the bound C1 depended on changes induced in the IgG molecule by straddling hapten molecules at varying distances.

Animals↗
PubMed1982

Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density.

Rabbit anti-methotrexate (MTX) IgG antibody was used to study the effect of MTX density on sheep red cells on the lysis of cells by complement (C). Under conditions in which the density of IgG did not vary, the number of lytic IgG complexes remained approximately the same when the average distance between MTX molecules was between 5 and 7 nm, but decreased rapidly with an average distance less than 10 nm. The results were interpreted to mean that in addition to aggregation for IgG to acquire maximal C in fixing and activating properties, the angle of the Fab arms of the molecule must not be larger than about 50 to 60 degrees. The data also suggested IgG molecules with Fab angles of less than about 30 degrees might also not be able to induce C-mediated cell lysis.

Animals↗
PubMed1982

C4 does not bind to human and rabbit IgM during activation of the classical complement pathway on the red cell.

It has been known for many years that IgG-C4 complexes are generated during the activation of the classical complement pathway. Information regarding binding of C4 by IgM is not available. We studied the binding of human C4 by natural human and rabbit anti-hapten IgM under conditions in which the IgM was bound to hapten coupled to sheep red cells. We eluted the IgM by excess fluid phase hapten, reattached the eluted IgM to red cells coupled with hapten, and transferred the IgM from red cell-IgM-C4 complexes to red cells coupled with hapten. Analysis of the cells by radioimmunoassay and/or by hemolytic assays showed that no C4 was eluted from the cells with the IgM, that no C4 transferred from cell to cell with the IgM, and that the C4 remaining on the cells was hemolytically active. We concluded that in contrast to IgG, natural human and rabbit IgM at a cell surface failed to bind C4.

Animals↗
PubMed1981

In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.

Strong and heritable increase of immunogenicity of L1210 Ha leukemia has been obtained in vitro following multiple treatments with 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC), metabolically activated by mouse liver preparations (MLP) containing liver microsomes. The DTIC-treated leukemia (L1210D line) or the control line treated with MLP alone (L1210N line) showed comparable growth kinetics in vitro. However, progressive increase of immunogenicity occurred in leukemic cells in the course of in vitro treatments with DTIC plus MIP, but not with MLP alone, as evidenced by comparative studies on transplantation immunity elicited in BALB/c x DBA/2 F1 mice by graded inocula of L1210D or L1210N leukemia cells. In vitro experiments confirmed that metabolic transformation of DTIC is required for increasing tumor immunogenicity. In fact, L1210Ha cells became highly immunogenic when treated with DTIC in intact mice but not in animals metabolically depressed by CCl4. Immunochemotherapy experiments based on the antigenic cross-reactivity between the L1210D line and the original L1210Ha leukemia showed that i.p. administration of L1210D cells followed by 1,3-bis(2-chloroethyl)-1-nitrosourea treatment afforded marked protection in mice inoculated intracerebrally with the parental lymphoma. The present findings could provide an adequate in vitro technique for developing further studies on DTIC-mediated immunogenic changes of tumors, including human cancer cells growing in tissue culture.

Animals↗
PubMed1981

Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.

In vivo treatment of leukemic mice with the antitumor agent 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) results in early increase of tumor-associated immunogenicity which is expected to evoke host-versus-graft responses. However, transplantation immunity is severely impaired in DTIC-treated mice due to the immunodepressant activity of the drug. It follows that the DTIC-mediated increase of tumor immunogenicity effect cannot be of therapeutic value in ordinary conditions. In the present report, we describe the results of studies aimed at restoring immunocompetence of DTIC-treated mice by means of adoptive transfer of syngeneic lymphoid cells. Infusion of spleen cells into DTIC-treated mice failed to restore graft responsiveness even in allogeneic tumor-host combinations. However, when DTIC treatment was followed by administration of cytotoxic alkylating agents such as cyclophosphamide (CY) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), graft responsiveness was partially restored upon adoptive transfer of syngeneic splenocytes. (BALB/c X DBA/2) F1 (hereafter called CD2F1) mice bearing leukemia L1210 Ha were treated as follows: (a) DTIC for increasing the immunogenicity of the leukemic cells; (b) CY or BCNU; and (c) adoptive transfer of CD2F1 lymphocytes. The results showed that: (a) DTIC alone or DTIC plus spleen cells produced little or no increase in survival times with respect to untreated controls; (b) DTIC plus CY or BCNU increased survival times to a larger extent; and (c) the adoptive transfer of lymphocytes produced marked protection of leukemic mice when the hosts had been pretreated with DTIC plus CY or BCNU but not with CY or BCNU without DTIC. These data may provide a model for exploiting DTIC-induced increase of tumor immunogenicity for immunochemotherapeutic regimens.

Animals↗
PubMed1979

[Transfer in vivo of cytotoxic immune lymphocytes obtained in vitro in primary culture against a murine lymphoma antigenically altered by DTIC].

Specific cytotoxic T cells were obtained by coculturing "in vitro" normal spleen cells with inactivated histocompatible DTIC-altered lymphoma cells. The "in vivo" antitumor activity of such sensitized lymphocytes was evaluated by injecting a mixture of lymphocytes + tumor into the brains of lethally irradiated syngenic mice. The results indicated that such lymphocytes demonstrate antitumor activity against the same tumor but not against unrelated tumors.

Animals↗
PubMed1979

[Experimental models of immunochemotherapeutic synergism: study of the influence of the treatment schedule].

Graded doses of LSTPA or L1210 leukemia cells were injected ip or iv into fully compatible hosts or mice incompatible for Multiple Minor Histocompatibility Loci (MMHL). Three days later the animals were treated with single doses of BCNU, NM, DTIC and VCR. The results showed that NM and VCR could synergize with the weak anti-tumor immune responses of MMHL-histocompatible mice only upon ip injection of the tumor. If the same tumor has been injected iv, only BCNU could synergize with the host's antitumor response. On DTIC treatment, no synergistic effects were detectable for either route of tumor's challenge.

Animals↗